Altered significance of D'Amico risk classification in patients with prostate cancer linked to a familial breast cancer (kConFab) cohort. (6th April 2015)

• Record Type: Journal Article
• Authors: Bolton, Damien; Cheng, Yuan; Willems‐Jones, Amber J.; Li, Jason; Niedermeyr, Eveline; Mitchell, Gillian; Clouston, David; Lawrentschuk, Nathan; Sliwinski, Ania; Fox, Stephen; Thorne, Heather
• Is Part Of: BJU international. Volume 116:Number 2(2015:Aug.)
• Page Start: 207
• Page End: 212
• Publication Date: 2015-04-06
• Subjects: Genitourinary organs -- Diseases -- Periodicals; Genitourinary organs -- Surgery -- Periodicals; Urology -- Periodicals; 616.6
• DOI: 10.1111/bju.12792
• Languages: English
• ISSNs: 1464-4096

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="bju12792-sec-0001" sec-type="section"> <title>Objective</title> <p>To ascertain whether D'Amico risk classification is an accurate discriminator of prostate cancer mortality risk in <italic>BRCA2</italic> pathogenic mutation carriers and non‐carriers from a familial breast cancer cohort.</p> </sec> <sec id="bju12792-sec-0002" sec-type="section"> <title>Patients and Methods</title> <p>From family cancer pedigrees of patients evaluated through a familial breast cancer cohort all related men with a diagnosis of prostate cancer were identified. Genotyping of each patient or of the dominant familial <italic>BRCA2</italic> mutation was undertaken in each instance. Prostate cancers were analysed by <italic>BRCA2</italic> carrier vs non‐carrier status for their clinical progression and survival according to their D'Amico risk groups.</p> </sec> <sec id="bju12792-sec-0003" sec-type="section"> <title>Results</title> <p>For patients who were <italic>BRCA2</italic>‐mutation positive, there was no significant difference in cancer‐specific survival (CSS) between those patients who were graded as having D'Amico high‐ or intermediate‐risk disease. For patients who were <italic>BRCA2</italic>‐mutation negative, but were identified via a family cancer pedigree, there was no statistically significant difference in CSS between D'Amico high‐ and intermediate‐risk prostate cancers. Patients with D'Amico high‐risk disease who were <italic>BRCA2</italic>‐mutation carriers had substantially increased disease‐specific mortality compared with high‐risk non‐carriers (hazard ratio 2.94, <italic>P</italic> = 0.004).</p> </sec> <sec id="bju12792-sec-0004" sec-type="section"> <title>Conclusion</title> <p>D'Amico risk classification has limitations in predicting variations in prostate cancer‐specific mortality for this group of patients.</p> </sec> </abstract>